Maynard Um
-
-
-
-
-
-
-
BTIG on Maze Therapeutics (MAZE): 'Stock Weakness Likely Due to Proteinuria Increases Seen in Two Diabetic Patienst
-
-
-
-
-
-
-
Enliven Therapeutics stock surges 28% on Merck-Terns deal
-
-
-
-
-
-
-
Maze Therapeutics (MAZE) PT Raised to $50 at Leerink Partners
-
-
-
-
-
-
-
Maze Therapeutics (MAZE) PT Raised to $50 at H.C. Wainwright
-
-
-
-
-
-
-
H.C. Wainwright Starts Maze Therapeutics (MAZE) at Buy
-
-
-
-
-
-
-
Maze Therapeutics (MAZE) Opens At $16.12, IPO Priced At $16
-
435,412 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

